Status
Conditions
Treatments
About
The study participants' relevant medical records will be collected and reviewed for the retrospective subjects and after obtaining informed consent for the prospective subjects. The study materials that will be used will include blood tests, transvaginal ultrasound and magnetic resonance imaging (MRI). The study will involve two study arms
Full description
The study participants' relevant medical records will be collected and reviewed for the retrospective subjects and after obtaining informed consent for the prospective subjects. The study materials that will be used will include blood tests, transvaginal ultrasound and magnetic resonance imaging (MRI). The study will involve two study arms:
Arm 1: Women with adenomyosis pretreated with levonorgestrel-releasing intrauterine device (LNG-IUS) and proceeding with the ICSI Arm 2: Women with adenomyosis pretreated with oral progestin "Dienogest" and proceeding with the ICSI Primary and secondary key measurements will be used in the study.
The primary measures will include:
The secondary key measures will include:
Ultrasound Serum β-HCG level Symptoms of pain and bleeding
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Patients diagnosed using both the transvaginal ultrasound study (TVS) and MRI criteria
The appearance of asymmetrical thickening of the myometrium Irregular cystic areas within the myometrium Linear striations radiating out from the myometrium
Patients ≤42 years old at the time of starting ICSI cycle
Cryopreserved embryo transfer cycles
The presence of at least one good cryopreserved day 3 embryo.
Exclusion criteria
354 participants in 2 patient groups
Loading...
Central trial contact
Eslam Fathy Fathy, M.Sc.; Wael Saad Saad El Banna El Banna, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal